Blood Test May Predict Future Cognitive Decline in Preclinical AD
Plasma p-tau217 can help identify amyloid-beta–positive individuals with preclinical Alzheimer's disease who are most likely to deteriorate in the coming years, new research suggests.
Medscape Medical News
source https://www.medscape.com/viewarticle/987960?src=rss
Medscape Medical News
source https://www.medscape.com/viewarticle/987960?src=rss
Comments
Post a Comment